Cyfra 21-1
| Material: | 1 ml serum (Stability in serum at 4°C – 8°C: > 14 days) 1 ml EDTA-plasma |
| Methods: | Ligandenassays → Chemilumineszenz-Immunoassay (CLIA) | Reference range | < 2,08 ng/ml |
| Indication | Non-small cell bronchial carcinoma |
| Please note | Cyfra 21-1 is an acidic protein from the group of cytokeratins. As it is present ubiquitous in the cells, increased serum concentrations can be demonstrated in numerous tumors. It has diagnostic relevance in the clarification and therapy monitoring of the non-small cell bronchial carcinoma. In the small cell bronchial carcinoma, NSE or chromogranin A are the tumor markers of choice. Benign illnesses only rarely lead to increased Cyfra 21-1 levels; here we would like to give the example of advanced renal insufficiency as the main cause for increased serum levels. |
| Accredited | ja |
More Results for the letter C
- C-peptide in the serum (CPEP)
- C1-esterase inhibitor (C1-INH) (C1EA, C1EH)
- Activity evaluation, protein evaluation
- C2-complement (C2S)
- C3-complement in the serum (C3)
- C3-nephritis factor (C3NF)
- C3NeF
- C4-complement in the serum (C4)
- CA 125 (CA 125)
- CA 15-3 (CA15)
- CA 19-9 (CA19)
- CA 72-4 (CA72)
- Cadmium (CAD)
- Cd
- Caeruloplasmin (α2-) (CAER(a2))
- Caffeine (COFF)
- Calcitonin (CALC)
- hCT, human calcitonin
- Calcium in serum (CA)
- Ca
- Calcium in urine (CAU)
- Calcium, ionized, in serum (CAI)
- Calprotectin (ECALP)
- Calymmatobacterium granulomatis (CALY)
- Donovaniosis
- Campylobacter jejuni/coli infection (KCAMP, ECAMP, CAMPG, CAMPA)
- Canary serum, feather, excrement antibodies (IgG) (CANA)
- Candida infection (KCAND)
- Cannabinoids (CANN)
- Tetrahydrocannabinol, delta-9 THC, cannabis, weed, marihuana, hash
- Carbamazepine (CARB)
- Carboxyhemoglobin (COHB)
- CO-Hb
- Cardiac muscle antibodies (HMA)
- Carnitine ratio: Acyl carnitine / free carnitine (CARNF)
- Carotene (β-) (CARO(b))
- Group of carotenoids with provitamine A activity
- Cartilage autoantibodies (KNOR)
- Catecholamines in plasma (KATP)